A B S T R A C T The purpose of the present series of experiments was to measure and compare the effects of an anticholinergic drug (isopropamide) and an antagonist of the histamine H2 receptor (metiamide) on foodstimulated acid secretion. Patients with duodenal ulcers were stimulated by a steak meal, and acid secretion was measured by in vivo intragastric titration. The largest dose of isopropamide that can be taken clinically without producing intolerable side effects (maximum tolerated dose) suppressed food-stimulated acid secretion by 35%. By contrast, metiamide in a 400-mg dose produced no side effects and almost completely abolished food-stimulated acid secretion. A dose-response curve revealed that a 50-mg dose of metiamide was required to suppress food-stimulated acid secretion by 50%. Further studies showed that metiamide and isopropamide are additive in suppressing food-stimulated acid secretion, and that metiamide has no effect on serum gastrin concentration or on gastric emptying.
INTRODUCTION
Histamine exerts physiologic and pharmacologic effects by interaction with at least two different receptors. The H1 receptors mediate the action of histamine on smooth muscle of the gut and bronchi, and this action is blocked by classic antihistamines (1) . In contrast the effects of histamine on the gastric parietal cell, on the guinea pig atria, and on the rat uterus are not blocked by the classic antihistamines. The histamine receptors in the stomach, guinea pig atria, and rat uterus that are not inhibited by the classic antihistamine drugs have been labeled H2 receptors by Black, Duncan, Durant, Ganellin, and Parsons (2) . These workers have synthesized two analogues of histamine, burimamide and metiamide, that competitively inhibit the action of histamine on the H2 receptors.
In animal studies H2-receptor antagonists have been shown to inhibit gastric acid secretion in response to histamine, pentagastrin, 2-deoxyglucose, and food (2, 3) . In man these drugs suppress basal and nocturnal acid secretion and acid secretion stimulated by pentagastrin and histamine (2, 4, 5) . The purpose of the present study was to measure the inhibitory effect of an H2-receptor antagonist on food-stimulated acid secretion in patients with duodenal ulcers. This is thought to be of special importance since food is the normal physiological stimulant of acid secretion, since patients with duodenal ulcers have an exaggerated secretory response to food (6) , and since food-stimulated acid secretion is poorly inhibited by currently available antisecretory drugs. Because 5-mg increments until blurring of vision occurred. When this occurred, the dose was decreased 5 mg, and this was defined as the maximum tolerated dose. With this dose all patients had mild dryness of the mouth. The maximum tolerated dose varied from 20 to 40 mg/dose in the six patients studied with this drug.
Food-stimulated acid secretion. Acid secretion rate was measured for 3 h after the meal by continuous intragastric titration, as described in a recent publication from our laboratory (6) . Meal samples were obtained every 2 min through a Levin tube, the pH was measured, and the sample was returned to the stomach. 0.3 N sodium bicarbonate was infused through a small polyvinyl tube at a rate required to maintain the pH at 5.0. The number of milliequivalents of bicarbonate required to prevent a fall of gastric pH below 5 is equal to the number of milliequivalents of acid secreted in response to food.
Basal and peak histamine response. Basal acid secretion and the peak secretion rate after 0.04 mg/kg histamine acid phosphate were measured by standard methods (9) . The results for each of our patients are shown in Table I . Note that the mean basal acid output was 12.4 meq/h and the mean peak acid output was 48.1 meq/h in this group of patients.
Hydrogen ion concentration was measured by the method of Moore and Scarlata (10) . The peak histamine response was calculated as the sum of the two highest consecutive 15-min secretion rates multiplied by 2 to express the results in milliequivalents per hour.
Gastric emptying. The amount of PEG (originally ingested with the meal) remaining in the stomach at 30, 60, and 180 min after the meal was calculated from the PEG concentration of the gastric contents multiplied by the estimated gastric volume. Gastric volume at 30 and 60 min was measured by a nonabsorbable marker dilution method similar to that reported by George (11 (12) . All samples were tested in duplicate in the same assay. Antibody 1296, rabbit antigastrin prepared by immunization with gastrin conjugated to bovine serum albumin, was used at a final dilution of 1: 300,000 (13) . Prior testing established that heptadecapeptide gastrin (G-17) and 34 amino acid "big gastrin" (G-34) were measured on an equimolar basis in this system. Cross reactivity with cholecystokinin is less than 0.5% for antibody 1296 (12) . Results were expressed as picograms per milliliter with natural human G-17-I used as standard.
Patient evalution. Before, immediately after, and 1 wk after each of the studies a complete blood count, urinalysis, blood urea nitrogen, creatinine, fasting blood sugar, serum glutamic oxalotransaminase, alkaline phosphatase, and bilirubin were obtained. An electrocardiogram was obtained before, during, and after each of the studies, and blood pressure and pulse rate were measured every 30 min during each 3-h test period. The patients were carefully observed for subjective symptoms.
RESULTS
Onset of action, peak effect, and duration of action with 300 mg metiamide. Fig. 1 shows the pattern of food-stimulated acid secretion when six duodenal ulcer patients were given either 300 mg of metiamide or placebo tablets 30 min before the meal. Acid secretion rate is plotted for every 30 min. With the placebo, acid secretion increased to 17 meq/30 min at 60 min after the meal and remained relatively steady at this level for the next 1 h. The placebo meal response in this group of patients is equivalent to 77% of their peak acid output (Table I) . Metiamide markedly inhibited acid secretion throughout the 3-h test period. The onset of action was noted during the first 30 min after the meal or within the first 60 min after the drug was ingested. At 60 min after the meal, metiamide reached its peak effectiveness and suppressed acid secretion from 17 to 3 meq/30 min.
When metiamide was given 15 min after rather than 30 min before the meal, its onset of action occurred during the second 30-min test period (i.e., from 15 to 45 min after dosage), its peak effect was delayed to the fifth 30-min test period, and suppression of acid secretion during the fourth, fifth, and sixth test periods was enhanced (Fig. 2) . Although the pattern of secretory inhibition can, therefore, be altered by timing of the dose in relation to the meal, the total inhibition of acid secretion during the 3-h study was the same with both regimens (Fig. 2, final bars) .
Effect of varying doses of metiamide on food-stimulated acid secretion. Fig. 3 shows the effect on foodstimulated acid secretion of 50, 100, 200, 300, and 400 mg of metiamide given orally 30 min before the meal in five duodenal ulcer patients as compared to a placebo. Milliequivalents of acid secreted for the total 3-h period is shown. With the 50-mg dose, acid secretion was reduced by 34 meq, from 107 to 73 meq (P < 0.05). When the patients were given 100 mg, acid secretion was suppressed by 63 meq, from 107 to 44 meq (P <0.05). With the 200-and 300-mg dose, acid secretion was not inhibited to a greater extent than with the 100-mg dose. However, when 400 mg was given, acid secretion was reduced by 91 meq, from 107 to 16 meq, which is significantly greater than the inhibition with the 100-mg dose (P < 0.025). The maximal inhibition of acid secretion with each dose of metiamide was also calculated. For example, with the 300-mg dose of metiamide, acid secretion was maximally inhibited by 82% (from 17 to 3 meq/30 min) during the second 30-min test period (Fig. 1) . The maximum inhibition with the other doses was calculated in a similar fashion, and the results are shown in Fig. 4 . The 50-mg dose maximally inhibited acid secretion by 50%. The 100-, 200-, and 300-mg dose inhibited secretion from 70 to 80%; these values are significantly greater than the inhibition with the 50-mg dose (P <0.05), but the inhibition with the 200-and 300-mg dose was not significantly different from the 100-mg dose. On the other hand the 400-mg dose inhibited secretion by 96%, and this is significantly greater than the inhibition with the 100-mg dose (P < 0.05). E 6 Effect of a maximum tolerated dose of isopropamide, of 300 mg metiamide, and of 300 mg metiamide plus isopropamide on meal-stimulated acid secretion in six patients with duodenal ulcers. The difference in total 3-h acid secretion between 300 mg metiamide plus isopropamide and 300 mg metiamide given alone is statistically significant by paired t test (P < 0.025).
Inhibition of Food-Stimulated Acid Secretion by H.-Receptor Antagonist z Iz (P < 0.025). 3-h acid secretion was suppressed to a greater extent by metiamide than by isopropamide in each of our six duodenal ulcer patients (See Table II ).
The effect of the combination of metiamide and isopropamide on food-stimulated acid secretion. Fig. 6 shows the effect of a combination of 300 mg metiamide plus a maximum tolerated dose of isopropamide on foodstimulated acid secretion in six duodenal ulcer patients as compared to a placebo, isopropamide alone, and 300 mg metiamide alone. The drug combination was more effective in suppressing food-stimulated acid secretion than was either of the drugs given alone. At 60, 90, and 120 min after the meal, acid secretion with the combination was less than 1 meq/30 min, and even at 180 min acid secretion was only 2.4 meq/30 min. All of the differences in total 3-h acid secretion were statistically significant by paired t test (P < 0.025). It is concluded, therefore, that the inhibitory effects of metiamide and isopropamide were additive and that the combination of these drugs suppressed acid secretion to a greater extent than either of the drugs alone. As shown in Table  II , 300 mg of metiamide combined with isopropamide was also more effective than a 400-mg dose of metiamide in suppressing food-stimulated acid secretion in each of our five duodenal ulcer patients. Effect of metiamide, isopropamide, and their combination on serum gastrin concentration. Serum gastrin concentration in response to a meal after 300 mg metiamide or placebo is shown in seven patients (Fig. 7A) . The rise in serum gastrin after the meal was similar with the placebo and with metiamide, and none of the differences are statistically significant by paired t test. Meal Meal FIGURE 7 Serum gastrin concentration in response to a meal after 300 mg metiamide in seven patients (A), isopropamide in five patients (B), or 300 mg metiamide plus isopropamide in five patients (C). Serum gastrin concentration at 0 time was obtained before the meal. None of the differences were statistically significant. cebo. Isopropamide had no effect on serum gastrin. As shown in Fig. 7C there was a slight increase in serum gastrin concentration after the drug combination as compared to the placebo, but this increase was not statistically significant.
Effect of metiamide, isopropamide, and their combination on gastric emptying. Gastric emptying as estimated by the percent PEG remaining in the stomach at' 30, 60, and 180 min after the meal is shown in Fig. 8 . Metiamide and isopropamide had no effect on gastric emptying of PEG (Fig. 8A and 8B) . The drug combination delayed emptying of PEG slightly but to a statistically significant degree only at 30 min after the meal (P < 0.05, Fig. 8C ).
Side effects of metiamide. There were no subjective side effects noted by any of our patients. Blood pressure, pulse, and respiration remained stable throughout each of the 3-h studies. One patient developed a slightly elevated serum glutamic oxalotransaminase that subsequently returned to normal. All other laboratory studies remained normal.
DISCUSSION
Ingestion of a protein-rich meal elicits a maximal or near maximal secretion of acid by the human stomach. The mechanism of this secretion is complex and is believed to involve the action and interaction of acetylcholine, gastrin, histamine, and inhibitory hormones such as secretin. Although the relative importance of these different substances in mediating the secretory response to a meal is unknown, reduction of food-stimulated acid secretion could theoretically result from appropriate manipulation of these stimulants and inhibitors. In the present series of experiments we have examined and compared the effects of an anticholinergic drug and a histamine H2-receptor antagonist on acid secretion stimulated by a steak meal in patients with duodena ulcers. Acid secretion was measured by in vivo intra gastric titration (6) .
When patients with duodenal ulcers were pretreated with a maximum tolerated oral dose of isopropamide food-stimulated acid secretion was inhibited by a maximum of 35%. This dose of anticholinergic drug is usually assumed to only or mainly inhibit the muscarinic actions of acetylcholine (14) , and these results suggest, therefore, that the muscarinic effects of acetylcholine play at least some role in mediating the gastric acid secretory response to food in duodenal ulcer patients. It is clear, however, that anticholinergic drugs in maximum tolerated doses can reduce food-stimulated secretion to only a modest extent. This is in contrast to basal (unstimulated) secretion, which is reduced from 50 to 80% by a maximum tolerated dose of various anticholinergic drugs (15, 16) .
Metiamide is a recently synthesized drug that is believed to antagonize the effect of histamine on the gastric parietal cell (17) . In hopes of defining the role of histamine and its antagonism on food-stimulated acid secretion in patients with duodenal ulcers, we studied the effect of 50, 100, 200, 300, and 400 mg of metiamide given orally 30 min before the food stimulus. It Doses of 100-300 mg inhibited food-stimulated secretion in our patients by 70-80%, and a 400-mg dose of metiamide inhibited secretion by 96% (Fig. 4) . If metiamide in oral doses of up to 400 mg is a specific inhibitor of the H2 receptor, as is generally assumed (17), these results indicate that histamine plays a dominant role in mediating food-stimulated acid secretion and that when the histamine receptor is sufficiently antagonized (i.e., with a 400-mg dose), food-stimulated acid secretion is nearly abolished. Although there is no unequivocal proof that metiamide inhibits acid secretion solely by virtue of antagonizing the histamine receptor, to our knowledge there is no evidence for any other mode of action of this drug.
Since a maximum tolerated dose of anticholinergic drug and a histamine receptor antagonist both inhibit food-stimulated acid secretion, the effect of the combination of isopropamide and metiamide was also measured. Isopropamide alone reduced acid secretion during the 3 h after the meal from 98 (Table  II) . Third, the onset of action, duration of action, and peak effect of the drug have been established. If metiamide is given before meals, it is most effective during the early postprandial period, whereas if it is given after meals, it is most effective during the 2nd h after eating. The duration of action is at least 3 
